Mirasol Pathogen Reduction Technology treatment does not affect acute lung injury in a two-event in vivo model caused...

Area of Science:

• Blood Component Processing
• Transfusion Medicine
• Immunology

Background:

• Mirasol Pathogen Reduction Technology (PRT) uses riboflavin and UV light to inactivate pathogens.
• Neutrophil priming activity accumulates during blood component storage and is linked to transfusion-related acute lung injury (TRALI).
• This study investigates PRT's effect on priming activity in stored packed red blood cells (PRBCs) and platelet concentrates (PCs).

Purpose of the Study:

• To determine if PRT treatment influences the generation of neutrophil priming activity during storage of PRBCs and PCs.
• To assess if PRT treatment affects the potential of stored blood components to elicit acute lung injury (ALI) in vivo.

Main Methods:

• PRT treatment was applied to half of collected plasma, PRBCs, and PCs, with the remainder serving as an unmodified control.
• Supernatants from stored components were collected and assayed for neutrophil (PMN) priming activity.
• A two-event in vivo model of TRALI was used to evaluate the effects of the supernatants.

Main Results:

• PRT treatment did not induce priming activity in plasma or alter priming activity during PRBC or PC storage compared to controls.
• Supernatants from stored, but not fresh, PRBCs and PCs caused ALI in the animal model, irrespective of PRT treatment.
• TRIMA-derived PCs showed significantly less priming activity than SPECTRA-derived PCs.

Conclusions:

• PRT treatment does not induce plasma priming activity or affect storage-induced priming activity in PRBCs or PCs.
• PRT treatment does not alter the capacity of stored PRBCs or PCs to cause ALI in a two-event in vivo model.
• The findings suggest PRT does not modify the TRALI-associated priming activity generated during routine blood component storage.